ARCHIVES

Transplant Is Viable Option For HIV+ Patients, Study Finds

This article is from The Cancer Letter archive.

Vol. 28 No. 2 | February 25, 2005

Download PDF Visit The Full Archive

Related Articles

Abraxane-Gemcitabine Combination Extends Overall Survival in Phase III Trial

January 31, 2014

Senate Committee Approves $1.74 Billion for NCI, Seeks Activation of Dietary Intervention Trial

October 19, 1990

House Committee Urges “Heat Shock” Cancer Center, But Can It Be Done?

July 24, 1998

Gleevec Approval Sets Record For FDA Review: 73 Days

May 25, 2001

Clinical Trials Approved By NCI In November

December 28, 2001

Minnesota Study Aimed At Finding Final Answer On Hemoccult Screening

July 24, 1987